Thursday, 1 August 2019

Precision Medicine Market 2019 - Opportunity, Driving Trends and deep study 2022

Market Research Future adds the “Global Precision Medicine Market Research Report – Forecast to 2022” report to their unique collection. The major market driving factor for precision medicine are patient’s involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others.
Precision medicine refers to medicines developed as per an individual’s genetic profile that helps as a guide for the prevention, diagnosis and treatment of diseases. The global precision medicine market was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2022. Thus the market is expected to perform a growth at a CAGR of 12.48% from 2015 to 2022.
The market constraints include potential threat to personal data, high diagnostic cost as a barrier, potential risk of hardware or software failure, stringent regulations and standards, lack of awareness about the possible applications of precision medicine, reimbursement policies and regulatory framework, limited knowledge about the application of test and techniques, lack of research and evidences creating hindrances in its application.
Key Players for Global Precision Medicine Market:
Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biomérieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa, Caris Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine
Key Findings:
  • The global precision medicine market is expected to reach USD 88.64 billion by 2022.
  • By ecosystem diagnostic tool companies holds the largest market share of precision medicine market and is expected to reach USD 27.56 billion by 2022.
  • By sub-market, company diagnostics holds the largest market share of precision medicine market and is expected to reach USD 21.32 billion by 2022.
Segmentation:
Global Precision Medicine market has been segmented on the basis of ecosystem, sub-market, therapeutics and region.
Regional Analysis
Globally North America is the largest market for global precision medicine. Europe is the second-largest market for global precision medicine. The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.
Browse Complete 313 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/precision-medicine-market-925

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Monday, 22 July 2019

Top trends in Cardiopulmonary Disease Diagnostics and Treatment Market by 2019

Market Scenario:
The cardiopulmonary disease is a general term used to describe a variety of different diseases and conditions related to heart and lungs. Cardio Vascular Disease is a complex disease with a wide variety of risk factors including those that are modifiable, such as physical inactivity, non-modifiable factors such as age, genes, congenital dispositions, and gender. Respiratory disease is a medical term that includes extreme conditions affecting the organs and tissues which make gas exchange possible in higher organisms. Depending upon the type of cardiopulmonary disease present the treatment options vary and may include changes in diet or lifestyle, use of medications issued on prescription or surgery. The most common cardiopulmonary diseases are hypertension, stroke, and coronary heart disease. Untreated, cardiopulmonary diseases can be deadly. Cardiopulmonary diseases are the major cause of death globally.
The substantial growth in the frequency of health conditions related to the lungs and heart is the key factor to boosts the growth of this market. Also, the increase in aged population and the rising frequency in cardiovascular and respiratory diseases is also anticipated to drive the global market over the forecast period. Exposure to nicotine, tobacco products, and others increases the risk of obtaining cardiopulmonary diseases.
Increase in the rise of advanced technological equipment for diagnosing the disease will drive market rate exponentially. However, the huge cost of treatment and the regulatory nature of government on pharmaceutical companies will hamper the growth of the market.
Key Players
  • Cardinal Health
  • Cosmed Medical
  • GE Healthcare
  • Halma plc
  • Hill-Rom Holdings, Inc.
  • Koninklijke Philips N.V.
  • MGC Diagnostics Corporation
  • NIHON KOHDEN CORPORATION
  • Schiller AG
  • Masimo Corporation
  • Vyaire Medical Inc
Segmentation
The global cardiopulmonary disease diagnostics and treatment market has been segmented on the basis of disease type, type, and end-user.
On the basis of disease type, the market has been classified as cardiovascular and respiratory diseases. The cardiovascular diseases are segmented into coronary artery disease, angina pectoris, myocardial infarction, dysrhythmia, hypertension, and others. The respiratory diseases are segmented into influenza, asthma, bronchitis, emphysema, cystic fibrosis, and others.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics and rehab centers, research institutes and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis market is segmented into an electrocardiogram (ECG), Holter monitoring, echocardiogram, stress test, cardiac catheterization, cardiac computerized tomography (CT) scan, cardiac magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), stress blood pressure monitors, pulse oximeters and spirometry. The treatment market is segmented into medications. The medications segment is further sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBS), anticoagulants, antiplatelet agents and others.
The European cardiopulmonary disease diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The cardiopulmonary disease diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiopulmonary disease diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
In the cardiopulmonary disease diagnostics and treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures.
 The European market is expected to hold the second largest market share. The market growth in this region can be attributed to rising frequency of cardiovascular disorders, increasing number of surgeries and increasing demand for advanced treatment procedures are boosting the European market.
The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism.
The market in the Middle East and Africa is expected to account for the smallest share of the global cardiopulmonary disease diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/cardiopulmonary-disease-diagnostics-treatment-market-6390
       
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Verrucous Carcinoma Market 2019 Market Challenge, Driver, Trends & Forecast to 2023

Market Insights
Verrucous Carcinoma typically debuts as an anomalous growth or as alteration in the constancy of an earlier potentially malignant ailment of the oral cavity. Verrucous Carcinoma is a rare, locally aggressive, clinically exophytic, low-grade, slow-growing, well-differentiated squamous cell carcinoma with nominal metastatic potential. It is unusual subtype of malignant ailment which affects oral cavity. Verrucous Carcinoma can affect all mucosal sites of the oral cavity. However, the frequency of malignant transformation of a leukoplakia to an OVC is considerably higher if they are in the gums in comparison to the tongue.
Verrucous Carcinoma is mainly caused by the snuffing of tobacco or chewing of tobacco. It is also referred to as snuff dipper's cancer. Verrucous Carcinoma mostly prevails at oral zones. The condition common in males within the age group 50 to 80 years. The increasing incidences of oral cancer primarily influences the market. Lifestyle factors such as smoking marijuana or tobacco and alcohol consumption mostly drives the Verrucous Carcinoma market. Additionally, growing consumption of alcohol, increasing adoption of sedentary lifestyle, increasing rates of sexually transmitted viruses by human papillomavirus, and family history of cancer prevalence contribute largely towards the development of the market. In 2015, the World Health Organization reported that 1.1 billion people smoked tobacco globally. This is likely to accelerate the market growth over the forecast period.
However, the high cost of surgical procedures, side effects associated with treatments, and expensive chemotherapy treatments are anticipated to limit the market growth to a certain extent.
Market Segmentation
The worldwide Verrucous Carcinoma market has been segmented based on treatment, end-user, and diagnosis.
Based on treatment, the Verrucous Carcinoma market has been segmented into radiation therapy, surgery, targeted drug therapy, and chemotherapy. Surgery has been sub-segmented into Mohs micrographic surgery and surgical excision. Chemotherapy has been sub-segmented into 5-fluorouracil, bleomycin, methotrexate, cisplatin, and others. Based on end-user, the Verrucous Carcinoma market has been segmented into ambulatory surgical centers, hospitals and clinics, research centers, diagnostic centers, and others. Based on diagnosis, the Verrucous Carcinoma market has been segmented into endoscopy, imaging tests, and biopsy. Imaging tests have been sub-segmented into magnetic resonance imaging, positron emission tomography scans, and computerized tomography scans.
Regional Analysis
The Americas represent the largest share in the global Verrucous Carcinoma market. The market growth is owing to the increasing healthcare expenditure and surging prevalence of Human Papillomavirus (HPV). As recorded by the Genital HPV Infection, Fact Sheet 2017, 79 million American adults were infested with HPV. Europe (Belgium, UK, Netherlands, and France) represents the second largest Verrucous Carcinoma market over the forecast period. Rising prevalence of head and neck cancer drives the Verrucous Carcinoma market in this region. The Cancer Research UK revealed that in 2015, there were12061 new instances of neck and head cancer. These statistics substantially drive the Verrucous Carcinoma market in Europe.
In 2017, Asia-Pacific was estimated to be the fastest growing region for the worldwide Verrucous Carcinoma market. The market has been expected to develop owing to the rising addiction to smoking. According to the World Health Organization, in 2015, 33.7% and 47.6% of people smoked tobacco in Japan and China, respectively. The Middle East and Africa holds the least market share due to lack of availability of trained healthcare professionals and low per capita income in the region. Nevertheless, the growing palliative and oncology care services both at the community and the hospital level are expected to influence the market positively.
Key Players
The global Verrucous Carcinoma market is dominated by key players such as Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Bristol-Myers Squibb Company (US), Eli Lilly and Company. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Europe), Pfizer Inc. (US), Novartis AG (Europe), and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:

Healthcare Asset Management Market 2019 Market Challenge, Driver, Trends & Forecast to 2023

Market Scenario
The healthcare asset management market to showcase an extraordinary 18.2% CAGR over the forecast period (2018-2023), revealed Market Research Future (MRFR) in a well-outlined report on the same market.
The healthcare asset management includes patient record management, easy access to maintenance record, locating medical equipment, and registering of the status of each equipment. Increasing demand for healthcare and the availability of varying types of treatment are creating a situation where easy access to everything is prized. This would help in quick and efficient service delivery to patients. When time is of the essence, then keeping everything at a hand’s distance becomes necessary. Healthcare asset management does that quite efficiently. MRFR, while having a detailed study of the healthcare asset management market, harps on segments and their volume-wise and value-wise valuation. In sync, it also analyses the factors that may play an important role in the coming years.
Patient safety gets the priority in the healthcare sector which can provide the much-needed traction to the market. Among the other factors, its ability to simplify the work process can be considered one of the major influencers. In addition, with rising investment in R & D, the sector is only going to flourish. However, accuracy issues and high installation cost can hamper the expected growth rate of the market.
Key Players
  • cenTrak,
  • Airista Flow,
  • GE Healthcare,
  • IBM Corporation,
  • Infor Inc.,
  • Tyco Security Products.,
  • Intelligent InSites,
  • Motorola Solutions, Inc.,
  • Radianse, JADAK (a Novanta Company),
  • Siemens Healthineers, Sonitor Technologies,
  • Stanley Black & Decker, Inc.,
  • Ekahau, Inc.
Segmentation
The healthcare asset management market has been segmented on the basis of product, application, and end-user.
On the basis of product, the market has been classified as real-time location systems (RTLS), radiofrequency identification (RFID) devices and ultrasound & infrared tags. The real-time location systems (RTLS) segment has been further divided into hardware, software and services. The hardware segment has been further divided into tags/badges and readers/interrogators.
The radiofrequency identification (RFID) devices have been classified as hardware, and software and services. the hardware segment has been divided tags, readers/interrogators, and accessories. The tags sub-segment has been segmented into passive tags and active tags. The passive tags segment has been divided into high-frequency (HF) tags, ultra-high-frequency (UHF) tags and low-frequency (LF) tags. Furthermore, the application segment has been sub-segmented into hospital asset management and pharmaceutical asset management. The hospital asset management segment includes equipment tracking and management, patient management, temperature and humidity monitoring, staff management and infection control and hand hygiene compliance. The pharmaceutical asset management segment includes drug anti-counterfeiting and supply chain management.
The market, by end-user, has been segmented into Hospital/Clinic, Laboratories, Pharmaceutical companies, Biotechnology.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The healthcare asset management market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The healthcare asset management market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The healthcare asset management market in the Middle East & Africa has been segmented into the Middle East and Africa.
The European healthcare asset management market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
Regional Summary
MRFR included regions such as the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA) in their report on the healthcare asset management market.
The Americas is a market that is highly evolved, both infrastructurally and technologically. High investment potential in the region enables various end-users in integrating the healthcare asset management market. These factors are going to play a big role in maintaining the premier position it is enjoying now in the global market.
Europe’s market is the second biggest one where the crisis of counterfeit drugs can be avoided with such effective methods. At the same time, the increasing investment for research and development sector can assure the market of better management technology in the coming years. The regional healthcare sector is relying much on the prosperity of healthcare asset management as it can ease the entire workflow to back the growing demands from patients. The AAPC market is all set to grow with the fastest CAGR during the forecast period. Rapid digitization in the healthcare sector is expected to boost the market. The MEA market can contribute a small part only as the region is technologically not that well-structured.
Browse Complete 85 Pages Premium Research Report Enabled with 90 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/healthcare-asset-management-market-6335

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Thursday, 18 July 2019

Laser Probe Market - Granular Market Report and Review, 2019

As per the analysis published by Market Research Future (MRFR), the global laser probe market is set to strike a CAGR of 9.11% during the forecast period 2018 to 2023. The valuation of the market is estimated to reach USD 1560.76 Mn by the end of 2023.
Laser is view as a highly advanced technology used in imaging diagnostics procedures. Advances in technology and increasing demand for diagnostic services are some of the factors supporting the growth of market. There is a growing need for effective diagnostic technologies, which is creating opportunities for the laser probe market.
The rising prevalence of diseases associated with diabetic retinopathy, cancer and age-related macular diseases has made diagnostics a key healthcare segment. Many of these conditions can have a severe impact on the eye sight. It is a known fact that a significant number of eye related issues are triggered by chronic diabetes. However, the severe infection and genetic factors are also frequently linked with laser probe. The American Academy of Ophthalmology stated that in 2016, more than 4 Mn people with diabetes in the US had visual complications. Demand for laser probe has also increased due to their growing application in dental procedures for periodontal diseases and caries.  The aforementioned factors will continue to support the growth of the market throughout the assessment period.
Competition Tracking:
Some of the notable players operating in the market include Alcon (Novartis), FCI, Reimers & Janssen GmbH, Transonic Systems Inc., OphthalMed LLC, Iridex Corporation, Bausch & Lomb Incorporated, ADInstruments, Quantel Medical, Omega Laser Systems Limited, Vitreq and Lumenis.
Segmental Analysis:
The report includes a thorough segmental analysis of the market based on probe type, product type, application and end user.
On the basis of product type, the market has been segmented into pulsed laser probes, continuous-wave (CW) laser probes and others. The continuous-wave (CW) laser probes segment currently accounts for the largest market share. In addition, the segment will continue to witness a steady growth during the forecast period. CW laser probes find widespread application in dermatological procedures such as wrinkle reduction, and scars or marks removal.
By probe type, the market has been segmented into cluster laser probe, single laser probe and others. The single laser probe segment currently accounts for the largest market share. The segment surpassed a valuation of USD 400 Mn in 2017. The cluster laser probe segment is projected to exhibit the strongest CAGR over 2023. Cluster laser probes are highly advanced and quickly gaining popularity. 
By application, the market has been segmented into dermatology, orthopedics, ophthalmology, dentistry, rheumatology and other. Of these, the ophthalmology segment accounted for the highest market share in 2017 and trends are likely to continue beyond 2018. Whereas, the dermatology segment is set to surge at the highest CAGR during the review period. This is primarily owing to the increased application of laser probes in various types of dermatological procedures.
By end-user, the market has been segmented into clinics, tertiary hospitals and others. Currently, the tertiary hospital segment accounts for the predominant share of the market. The currently market valuation of the segment is more than USD 500 Mn. This is attributed to the rapid proliferation of tertiary hospitals in urban and sub-urban areas.
Regional Outlook:
On the basis of region, the market has been segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa (MEA). North America and Latin America collectively command the most dominant share of the global laser probe market. The increasing prevalence of diseases such as cataract and arthritis and the rising demand for aesthetics is supporting the growth market in these two regions.According to the American Society for Nutrition, in 2016, close to 47% of the adults in the US had periodontal disease. In the same years, 586,662 minimally-invasive cosmetic procedures were performed for laser skin resurfacing. The region will remain a key destination for market players throughout the assessment period.
Browse Complete 120 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/laser-probe-market-7009
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Surgical Sealants and Adhesives Market 2019 Market Challenge, Driver, Trends & Forecast to 2023

Global Surgical Sealants and Adhesives Market is expected to grow significantly over the forecast period. It is anticipated that the market held a market value of USD 2.12 billion in 2017 and is projected to grow at a CAGR of 9.3% over the forecast period.
The factors such as growing prevalence and incidence of various disorders, growth in the number of accidents, and growth in the number of surgeries are expected to propel the growth of the market. According to the Centers for Disease Control and Prevention (CDC), in 2015, about 2.8 million people were hospitalized due to injuries. However, lack of reimbursements policy; and extensive clinical data requirements for launching products hamper the market growth over the forecast period.
Key players
  • Bard, Inc. (US),
  • Johnson & Johnson (UK),
  • Baxter International, Inc. (US),
  • Medtronic plc (US),
  • Braun Melsungen AG (Germany),
  • Cohera Medical, Inc. (US),
  • Sanofi Group (France),
  • Sealantis, Ltd (Israel),
  • Vivostat A/S (Denmark),
  • Ocular Therapuetix, Inc. (US)
Regional Analysis
Geographically, the Americas is expected to dominate the global surgical sealants and adhesives market owing to the presence of well-developed healthcare sector, growing prevalence and incidence of various disorders, growth in the number of accidents, and growth in the number of surgeries. Europe is expected to hold the second largest position in the global surgical sealants and adhesives market owing to the growing prevalence of chronic diseases coupled with increasing adoption of new technologies. Asia-Pacific is expected to be the fastest growing market owing to the large population base of the diabetic patients and increasing developments in healthcare segment. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global surgical sealants and adhesives market.      
Segmentation
The global surgical sealants and adhesives market has been segmented into product, indication, application, and end user.
Based on product, has been segmented into natural/biological sealants and adhesives and synthetic and semisynthetic sealants and adhesives. The natural/biological sealants and adhesives and synthetic segment is accounted for the largest share segment of the market in 2017.
The market, by indication, has been segmented into surgical hemostasis, tissue sealing, and tissue engineering.
The market, by application, has been segmented into general surgeries, cardiovascular surgeries, central nervous system surgeries, orthopedic surgeries, urological surgeries, and others.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/surgical-sealants-and-adhesives-market-7005
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Particle Therapy Market 2019–By Identifying the Key Market Segments and Key players holding market share

Particle therapy is one of the world's most advanced areas of external beam radiation therapy applied to oncology. This technique saves healthier radiation tissue better than conventional photon therapy. These particles have more favorable physical intrinsic properties that reduce the intake dose to approximately 50% of the dose in a clinically relevant target.
The Global Particle Therapy Market is accounted for USD 790.45 million in 2017 and expected to register 9.1% CAGR during the forecast period (2018–2023). 
The rising prevalence of cancer population, low risk of treatment induced disorders, potential for retreatment owing to low radiation dose, and rising number of particle therapy centers across the world are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by the top players such as new product launches are contributing to the growth of the market. For instance, in December 2017, Advanced Oncotherapy plc announced that it secures the fresh funding of USD 46.75 million from which USD 37.5 million of funds coming from a new Chinese investor. The lack of adequate reimbursement policy and high costs involved in the establishment of these centers may hamper the growth of the market during the assessment period.
Key Players
Some of the key players in the global particle therapy market are Advanced Oncotherapy PLC., Danfysik A/S, Hitachi, Ltd., Ion Beam Applications Sa (IBA), Mevion Medical Systems, Inc., Optivus Proton Therapy, Inc., Protom International, Inc., Provision Healthcare, LLC, Sumitomo Heavy Industries, Ltd., Varian Medical Systems, Inc.
Regional Analysis:
The market is likely to dominate by Americas during the forecast period owing to the increasing prevalence of cancer patients, rising government focused towards establishment of particle therapy centers for treatment, and well-established healthcare sector in the region. The European market is expected to be the second-largest due to government funding and support of the healthcare sector, coupled with increasing research and development. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to technological development, increasing adoption of advance treatment from developed countries, and favorable government initiatives for healthcare facilities. The market in the Middle East & Africa is likely to account for the smallest share of the global particle therapy market.
Segmentation:
The Global Particle Therapy Market has been segmented on the basis of type, product & service, cancer type, system, and application.On the basis of type, the market has been classified as proton therapy and heavy ion therapy. The market, by product and services, has been segmented into products and services. Products are further segmented into cyclotrons, synchrotrons, and synchrocyclotrons. Based on cancer type, the market has been segmented into prostate cancer, lung cancer, pediatric cancer, head and neck cancer, breast cancer, and others. The market, by system, has been segmented into multi-room systems and single-room systems. On the basis of application, the market has been classified as treatment applications and research applications. The pediatric cancer segment is expected to hold the largest market share of the particle therapy market, by cancer type, during the forecast period. Also, research applications to register the highest CAGR in the global particle therapy market during the forecast period.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The particle therapy market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European particle therapy market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The particle therapy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The particle therapy market in the Middle East & Africa has been segmented into the Middle East and Africa. 
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/particle-therapy-market-7000


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)